Detailed Abstract
[Liver Oral Presentation 4 - Transplantation]
[LV OP 4-3] Pegylated interferon versus direct-acting antiviral agents pre-emptive treatment of HCV after living donor liver transplantation
Jae Hyun KWON, Gi-Won SONG, Shin HWANG, Ki-Hun KIM, Chul-Soo AHN, Deok-Bog MOON, Tae-Yong HA, Dong-Hwan JUNG, Gil-Chun PARK, Sung-Gyu LEE
Division of Liver Transplantation and Hepatobiliary Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Korea, Korea
Introduction : HCV universally recurs after liver transplantation. Although the introduction of direct-acting antiviral agents (DAAs) has revolutionized the treatment of HCV infection, no optimal treatment for HCV recurrence after liver transplantation has been developed.
Methods : This study retrospectively evaluated the efficacy of DAAs as a pre-emptive treatment for recurrent HCV infection after living donor liver transplantation (LDLT). From January 2010 to December 2016, 105 patients received LDLT followed by either pegylated interferon (PegIFN) or a DAA-based regimen to treat recurrent HCV. All antiviral treatments were pre-emptive.
Results : After LDLT, 70 patients received PegIFN and 35 received a DAA. Genotype 1b was the most common HCV type (61.9%), followed by 2a (27.6%). Twenty-two recipients in the DAA group were treated with ledipasvir/sofosbuvir, nine received daclatasvir plus asunaprevir, three received sofosbuvir, and one received sofosbuvir plus daclatasvir. All 35 patients (100%) in the DAA group achieved a sustained virologic response (SVR), a percentage significantly higher than that (71.4%) in the PegIFN group (p
Conclusions : DAA-based regimens are an effective treatment for HCV recurrence after LDLT, resulting in an improved SVR and better graft survival than PegIFN-based treatments.
Methods : This study retrospectively evaluated the efficacy of DAAs as a pre-emptive treatment for recurrent HCV infection after living donor liver transplantation (LDLT). From January 2010 to December 2016, 105 patients received LDLT followed by either pegylated interferon (PegIFN) or a DAA-based regimen to treat recurrent HCV. All antiviral treatments were pre-emptive.
Results : After LDLT, 70 patients received PegIFN and 35 received a DAA. Genotype 1b was the most common HCV type (61.9%), followed by 2a (27.6%). Twenty-two recipients in the DAA group were treated with ledipasvir/sofosbuvir, nine received daclatasvir plus asunaprevir, three received sofosbuvir, and one received sofosbuvir plus daclatasvir. All 35 patients (100%) in the DAA group achieved a sustained virologic response (SVR), a percentage significantly higher than that (71.4%) in the PegIFN group (p
Conclusions : DAA-based regimens are an effective treatment for HCV recurrence after LDLT, resulting in an improved SVR and better graft survival than PegIFN-based treatments.
SESSION
Liver Oral Presentation 4
Room C 3/31/2018 8:30 AM - 9:20 AM